Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/25993
Title: | STAT3 Signalling via the IL-6ST/gp130 Cytokine Receptor Promotes Epithelial Integrity and Intestinal Barrier Function during DSS-Induced Colitis. | Austin Authors: | Pang, Lokman;Huynh, Jennifer;Alorro, Mariah G;Li, Xia;Ernst, Matthias ;Chand, Ashwini L | Affiliation: | Department of Mathematics and Statistics, La Trobe University, Bundoora, VIC 3083, Australia Olivia Newton-John Cancer Research Institute La Trobe University School of Cancer Medicine, Heidelberg, VIC 3084, Australia |
Issue Date: | 12-Feb-2021 | Date: | 2021-02-12 | Publication information: | Biomedicines 2021; 9(2); 187 | Abstract: | The intestinal epithelium provides a barrier against commensal and pathogenic microorganisms. Barrier dysfunction promotes chronic inflammation, which can drive the pathogenesis of inflammatory bowel disease (IBD) and colorectal cancer (CRC). Although the Signal Transducer and Activator of Transcription-3 (STAT3) is overexpressed in both intestinal epithelial cells and immune cells in IBD patients, the role of the interleukin (IL)-6 family of cytokines through the shared IL-6ST/gp130 receptor and its associated STAT3 signalling in intestinal barrier integrity is unclear. We therefore investigated the role of STAT3 in retaining epithelial barrier integrity using dextran sulfate sodium (DSS)-induced colitis in two genetically modified mouse models, to either reduce STAT1/3 activation in response to IL-6 family cytokines with a truncated gp130∆STAT allele (GP130∆STAT/+), or by inducing short hairpin-mediated knockdown of Stat3 (shStat3). Here, we show that mice with reduced STAT3 activity are highly susceptible to DSS-induced colitis. Mechanistically, the IL-6/gp130/STAT3 signalling cascade orchestrates intestinal barrier function by modulating cytokine secretion and promoting epithelial integrity to maintain a defence against bacteria. Our study also identifies a crucial role of STAT3 in controlling intestinal permeability through tight junction proteins. Thus, therapeutically targeting the IL-6/gp130/STAT3 signalling axis to promote barrier function may serve as a treatment strategy for IBD patients. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/25993 | DOI: | 10.3390/biomedicines9020187 | ORCID: | 0000-0001-7134-989X 0000-0002-1245-729X |
Journal: | Biomedicines | PubMed URL: | 33673239 | ISSN: | 2227-9059 | Type: | Journal Article | Subjects: | IL-6ST/gp130 STAT3 colitis inflammation intestinal barrier function |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.